Huntsman Cancer Institute

2000 Circle of Hope Dr.
Salt Lake City, UT 84112
+1 801-662-4700

Huntsman Cancer Institute (HCI) is part of University of Utah Health. Every year, HCI serves thousands of cancer patients from Utah and the surrounding states. HCI also teaches and trains future doctors, nurses, and scientists.

HCI is the only National Cancer Institute-Designated Cancer Center in the Intermountain West. This means it meets the highest national standards for cancer care and research and receives support for its scientific endeavors.

HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer.

Research Team

Principal Investigator

Luke Maese, DO

Assistant Professor, Pediatric Hematology/Oncology

Dr. Luke Maese received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital.  He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Assistant Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer genetics. He is co-director of the Leukemia/Lymphoma program at PCH, serves as a member of the Family Cancer Assessment Clinic (FCAC) at HCI, and is a member of the Schiffman lab at HCI.

Dr. Maese’s interests in investigation are translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on cancer predisposition, and in particular, predisposition to malignant hematopoietic disorders. Additionally he seeks to answer if the genetic information obtained can be used clinically to better understand relapsed pediatric cancer, therefore informing future treatment. To that end he serves as the primary investigator for several early phase trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

As a member of the teaching faculty, Dr. Maese has a commitment to teaching and mentoring of young learners. He serves as the primary mentor for pediatric hematology/oncology fellows and the course director for Foundations in Personalized Health, a class that is an integral part to the newly accredited certificate in Personalized Medicine offered through the University of Utah School of Medicine.

"Through an emphasis on exploration of disease mechanisms and then translating those discoveries to the clinic, POETIC is at the forefront in the fight against pediatric cancer."

-Dr. Luke Maese

* indicates required

Join our quarterly newsletter

Receive updates on POETIC new projects and activities.

 Pediatric Oncology Experimental Therapeutics Investigators' Consortium

© Copyright 2023 |   Website designed by Amanda M. Buckley

Connect

toll-free
(650) 736-0269

email
poeticdcc@stanford.edu